Although neither BAP1 nor CDKN2A mutations provide absolute specificity in diagnosing malignant mesothelioma, they remain invaluable adjuncts for differentiating PM from benign pleural lesions and prognostic assessment. Here, CDKN2A is linked to malignant mesothelioma.